Curis, Inc.
CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-89ā¦ read more
Healthcare
Biotechnology
23 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.83
Price+8.93%
$0.15
1Y
Price
Market Cap
$22.873m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$11.405m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$38.919m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$4.88
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
-$13.986m
$29.234m
Assets$43.220m
Liabilities$32.466m
DebtDebt to Assets
111.1%
-0.9x
Debt to EBITDAFree Cash Flow
-$30.457m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company